Verzenio (abemaciclib) has just gained its first approval in HR+/HER2- metastatic breast cancer, but the failure in non-small cell lung cancer (NSCLC) limits the drug's growth options.

Eli Lilly’s Verzenio is already one of its fastest-growing products, but could go up another gear following a pair of FDA approvals that expand its eligible patient population – particularly ...

These patients were then randomized into three equal groups to receive imlunestrant monotherapy, a combination of imlunestrant and Lilly’s blockbuster breast cancer drug Verzenio (abemaciclib ...

Eli Lilly and Co. announced Monday that it is buying Boston-based Scorpion Therapeutics and its targeted breast cancer ...

Indianapolis, Indiana-based Eli Lilly and Company (LLY) is a leading pharmaceutical company that sells Trulicity, Verzenio and Taltz drugs. The company discovers, develops, and markets human ...

Lilly’s current offerings include Verzenio for early and metastatic breast cancers. Verzenio, which Lilly has heavily advertised in recent years, is a top seller for Lilly, with sales of almost ...